Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $54
Veracyte, Inc.
Veracyte, Inc. VCYT | 0.00 |
Piper Sandler analyst David Westenberg maintains Veracyte (NASDAQ:
VCYT) with a Overweight and lowers the price target from $66 to $54.